aceRed Queen Bio is using AI to design antibodies for future viruses, WSJ says
OpenAI-backed Red Queen Bio uses AI to design antibodies against bird flu and future viruses, the WSJ reports. It has raised $36M in total.
In brief
On September 28, 2026, TNW reported on WSJ coverage of Red Queen Bio, an OpenAI-backed company that uses AI to design antibodies against bird flu and future viruses, and that has raised $36M in total.
The development matters for pandemic preparedness because AI-designed antibodies could accelerate response to emerging threats, but the source provides no evidence of efficacy, safety testing, or deployment, leaving real-world impact unproven at the time of reporting.
Main points
- Red Queen Bio is described as OpenAI-backed.
- The company's stated application is designing antibodies against bird flu and future viruses.
- The information is attributed to WSJ reporting, summarized by TNW.
- The company has raised $36M in total according to the report.
The gain
AI is being used to design antibodies intended to target bird flu and other future viruses.
The rundown
TNW summarized WSJ reporting on September 28, 2026 that Red Queen Bio is OpenAI-backed and focused on AI-designed antibodies.
The brief report also notes financing, stating the company has raised $36M in total, but provides no technical details, timelines, or clinical validation data.
Sources
- JournalismTNW2026-09-28
Toward Clinically Interpretable Perioperative Decision Support: Explainable Machine Learning for 30-Day Postoperative Mortality Prediction
The American Surgeon™
Three-Dimensional Point-Cloud Learning for Patient-Specific Deep Brain Stimulation Motor Response Prediction in Parkinson Disease
BME Frontiers
Distinct clinical patterns of preterm infants vulnerable to intestinal injury identified by unsupervised clustering
Pediatric Research
The debate